NeuBase Therapeutics, Inc. Common Stock
NBSE
NBSE was delisted on the 10th of May, 2024.
57 hedge funds and large institutions have $55.8M invested in NeuBase Therapeutics, Inc. Common Stock in 2014 Q2 according to their latest regulatory filings, with 33 funds opening new positions, 16 increasing their positions, 4 reducing their positions, and 11 closing their positions.
300% more repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 4
200% more first-time investments, than exits
New positions opened: 33 | Existing positions closed: 11
79% more capital invested
Capital invested by funds: $31.1M → $55.8M (+$24.7M)
63% more funds holding
Funds holding: 35 → 57 (+22)
37% less call options, than puts
Call options by funds: $4.99M | Put options by funds: $7.9M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VAM
Visium Asset Management
New York
|
+$10.4M |
| 2 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$4.87M |
| 3 |
VM
VHCP Management
New York
|
+$4.49M |
| 4 |
LOAMU
Lombard Odier Asset Management (USA)
New York
|
+$2.82M |
| 5 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
+$1.75M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EI
EAM Investors
Solana Beach,
California
|
-$2.23M |
| 2 |
BIM
Bogle Investment Management
Newton Lower Falls,
Massachusetts
|
-$880K |
| 3 |
SH
Scepter Holdings
Fort Worth,
Texas
|
-$785K |
| 4 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$663K |
| 5 |
GC
Gratia Capital
Los Angeles,
California
|
-$658K |
NBSE Hedge Fund Activity: Q2 2014 in Review
57 of the 3,480 institutional investors tracked by Wall St. Rank reported a position in NeuBase Therapeutics, Inc. Common Stock (NBSE) for Q2 2014, worth a combined $55.8M — up 79% from $31.1M a quarter earlier.
Buyers outnumbered sellers: 33 funds opened new NBSE positions and 11 closed out — a net gain of 22 holders — while 16 added to existing stakes and 4 trimmed.
The largest buyer was Visium Asset Management, opening a new position worth an estimated $10.4M. The largest seller was EAM Investors, exiting entirely with an estimated $2.23M sold.
- 57 institutional investors held NeuBase Therapeutics, Inc. Common Stock (NBSE) as of Q2 2014, up from 35 in Q1 2014.
- Funds reported $55.8M of NeuBase Therapeutics, Inc. Common Stock stock for Q2 2014, up 79% quarter-over-quarter.
- 33 funds opened new NeuBase Therapeutics, Inc. Common Stock positions in Q2 2014 and 11 closed out, a net change of +22 holders.
- The largest NeuBase Therapeutics, Inc. Common Stock buyer in Q2 2014 was Visium Asset Management, an estimated $10.4M added.
- The largest NeuBase Therapeutics, Inc. Common Stock seller in Q2 2014 was EAM Investors, an estimated $2.23M sold.
Based on aggregated 13F filings for Q2 2014.